Lipocine Announces Tlando NDA PDUFA Action Date of November 9, 2019

SALT LAKE CITY, May 14, 2019 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the U.S. Food and Drug Administration ("FDA") has...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news